This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bracho, F. Articles by Cairo, M. S. Search for Related Content PubMed PubMed Citation Articles by Bracho, F. Articles by Cairo, M. S.

A Phase I Clinical, Pharmacological, and Biological Trial of Interleukin 6 Plus Granulocyte-Colony Stimulating Factor after Ifosfamide, Carboplatin, and Etoposide in Children with Recurrent/Refractory Solid Tumors: Enhanced Hematological Responses but a High Incidence of Grade III/IV Constitutional Toxicities¹

Lombardi Cancer Center, Georgetown University Hospital, Washington, DC 20007 [F. B.]; University of Southern California School of Medicine, Los Angeles, California 90033 [M. D. K., W. L-M.]; Children’s Hospital of Orange County, Orange, California 92668 [V. S.]; Children’s Hospital of Los Angeles, Los Angeles, California 90027 [S. B., R. S.]; University of Minnesota Cancer Center, Minneapolis, Minnesota 55455 [B. R. B., A. P-M.]; Mayo Clinic, Rochester, Minnesota 55905 [M. M. A., J. M. R.]; Children’s National Medical Center, Washington, DC 20010 [G. H. R.]; and Babies and Children’s Hospital, Columbia University, New York, New York 10032 [V. D., C. v. d. V., M. S. C.]

A Phase I trial was conducted to determine the safety, biological activity, and hematopoietic recovery by the combination of interleukin 6 (IL-6) and granulocyte-colony stimulating factor (G-CSF) after myelosuppressive chemotherapy in children. Patients <22 years of age at diagnosis with either recurrent or refractory solid tumors received ifosfamide 1,800 mg/m²/day x 5 days, carboplatin 400 mg/m²/day x 2 days, and etoposide 100 mg/m²/day x 5 days, followed by daily s.c. G-CSF (5 µg/kg/day) and IL-6 (2.5, 3.75, or 5.0 µg/kg/day). Pharmacokinetic, proinflammatory mediator levels, hematopoietic colony assays, and cytokine receptor expression studies were performed during course one. Nineteen patients were evaluable for toxicity and received IL-6 at doses of 2.5 (n = 8), 3.75 (n = 5), or 5.0 (n = 6) µg/kg/day. Dose-limiting constitutional toxicity occurred in two of six patients at 5.0 µg/kg/day, two of five patients at 3.75 µg/kg/day, and two of eight patients at 2.5 µg/kg/day. The maximum tolerated dose (MTD) exceeded the lowest dose tested. Because of lack of drug availability, an MTD was not established. The maximum concentration of IL-6 (2.5 µg/kg/day) was 0.799 ± 1.055 ng/ml (mean ± SD). During the first course, the median time to absolute neutrophil count 1,000/mm³ and platelets 100,000 mm³ was estimated at 19 and 23 days, respectively. Peripheral blood progenitor cells expressing receptors to IL-3, IL-6, and G-CSF increased significantly over baseline (P < 0.05). After the first dose of IL-6, IFN- levels were abnormal in 13 patients, and IL-1ß levels were abnormal in 10 patients. IL-6 has a high incidence of constitutional toxicity and a lower MTD in children compared with adults. In vivo use of IL-6 in children after chemotherapy remains limited. However, IL-6 may be more optimally investigated in children under ex vivo conditions.

This article has been cited by other articles:

				A. L. Angiolillo, V. Davenport, M. A. Bonilla, C. van de Ven, J. Ayello, O. Militano, L. L. Miller, M. Krailo, G. Reaman, and M. S. Cairo A Phase I Clinical, Pharmacologic, and Biologic Study of Thrombopoietin and Granulocyte Colony-Stimulating Factor in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Recurrent or Refractory Solid Tumors: A Children's Oncology Group Experience Clin. Cancer Res., April 1, 2005; 11(7): 2644 - 2650. [Abstract] [Full Text] [PDF]

				W.-H. Shen, J.-H. Zhou, S. R. Broussard, G. G. Freund, R. Dantzer, and K. W. Kelley Proinflammatory Cytokines Block Growth of Breast Cancer Cells by Impairing Signals from a Growth Factor Receptor Cancer Res., August 15, 2002; 62(16): 4746 - 4756. [Abstract] [Full Text] [PDF]